Table 2. Meta-analysis of the association between CYP1A1 MspI polymorphism and renal cell carcinoma risk.
| N | C vs. T (allele model) | CC vs. TT (homozygous model) | CC vs. TT + CT (recessive model) | CC +CT vs. TT (dominant model) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95%CI) | POR | Ph | OR (95%CI) | POR | Ph | OR (95%CI) | POR | Ph | OR (95%CI) | POR | Ph | ||
| Overall | 3 | 1.49(1.03–2.16) | 0.035 | 0.010 | 1.64(1.13–2.40)* | 0.010* | 0.190 | 1.35(0.94–1.93)* | 0.105* | 0.459 | 1.72(1.07–2.76) | 0.026 | 0.013 |
| HWE test | |||||||||||||
| HWE | 1 | 1.15(0.87–1.52) | 0.324 | - | 1.23(0.70–2.17) | 0.474 | - | 1.12(0.66–1.91) | 0.670 | - | 1.22(0.84–1.77) | 0.303 | - |
| Non-HWE | 2 | 1.71(1.11–2.62) | 0.014 | 0.014 | 2.10(1.26–3.49)* | 0.004* | 0.251 | 1.57(0.97–2.57)* | 0.069* | 0.405 | 2.12(1.60–2.81)* | <0.001* | 0.068 |
OR odds ratio, 95% CI 95% confidence interval, POR P value for the pooled Ors, Ph P value for heterogeneity analysis.
*Estimates for fixed–effects model.